Ernexa Therapeutics (ERNAW) Assets Average (2011 - 2026)

Ernexa Therapeutics (ERNAW) has 16 years of Assets Average data on file, last reported at $8.2 million in Q1 2026.

• Quarterly Assets Average rose 58.57% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (up 58.57% YoY) and the FY2025 annual result came in at $5.6 million, down 79.59% from the prior year.
• Assets Average climbed to $8.2 million in Q1 2026, from $6.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $50.7 million in Q4 2023 to a low of $5.2 million in Q1 2025.
• A 5-year average of $24.9 million and a median of $23.9 million in 2022 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2024 — Assets Average soared 164.23% — and 2025, when it plunged 89.55%.
• Tracing ERNAW's Assets Average over 5 years: stood at $21.6 million in 2022, then soared by 134.65% to $50.7 million in 2023, then tumbled by 87.19% to $6.5 million in 2024, then decreased by 7.55% to $6.0 million in 2025, then surged by 36.41% to $8.2 million in 2026.
• The last three Assets Average figures came in at $8.2 million (Q1 2026), $6.0 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.